Winst gevend schreef op 19 november 2019 20:02:
BioCryst vergelijkt CINRYZE patiënten HAEGARDA patiënten en TAKHZYRO patiëntenSlide 16 shows that 79 of the 100 patients in our survey reported using injectable or infused HAE prophylaxis therapies, 63% of CINRYZE, 60% of HAEGARDA and 47% of TAKHZYRO patients reported they are very willing to use BCX7353. We analyzed responses even further by looking at those patients who reported being very satisfied with their current injectable or infused therapy, again, measured as top 3 box scores on an 11-point scale. You can see in the light green columns that half of the patients who reported being very satisfied with their current injectable therapies are also very willing to use 7353.
Turning to Slide 17. You can see that no drug is perfect, and patients continued to have breakthrough attacks on injectable and infused prophylaxis therapies. The mean number of attacks reported over the past 3 months among CINRYZE patients was 1.6 attacks; HAEGARDA, 0.9 attacks; and TAKHZYRO, 1.8 attacks.
Op zijn minst een opmerkelijke uitkomst en openbaring van feiten.